Health

US FDA approves Crinetics’ oral pill for rare hormone disorder

US FDA approves Crinetics' oral pill for rare hormone disorder

The drug, chemically known as paltusotine and to be sold under the brand name Palsonify, was approved to treat acromegaly, a rare condition in which the pituitary gland in the brain produces excess growth hormone, causing the bones, organs and other tissues to grow bigger. This is caused due to a tumor on the pituitary gland.
Sign up here.
According to the U.S. National Institutes of Health, scientists estimate about 3 to 14 of every 100,000 people have been diagnosed as having acromegaly.
Reporting by Bageshri Banerjee, Sneha S K and Siddhi Mahatole in Bengaluru; Editing by Shailesh Kuber and Krishna Chandra Eluri